Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma.
bone metastasis
radiographical efficacy
renal cell carcinoma
skeletal-related event
systemic treatment
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
25
02
2020
accepted:
24
08
2020
entrez:
29
9
2020
pubmed:
30
9
2020
medline:
30
9
2020
Statut:
ppublish
Résumé
Enlarged bone metastasis from renal cell carcinoma (RCC) can cause skeletal-related events, and thus treatment to inhibit the growth of bone metastases is often required. Although radiotherapy for RCC bone metastases can achieve a certain degree of local control, evidence is lacking regarding the effects of systemic therapy to improve bone metastasis. The present study aimed to assess the treatment efficacy of targeted therapy and immune checkpoint inhibitors, and to determine whether systemic therapy without radiotherapy can shrink bone metastases of RCC. The present study retrospectively reviewed 44 patients with RCC with bone metastases treated via systemic therapy, including targeted therapy or immune checkpoint inhibitors. Patients were divided into two groups: Those who underwent systemic therapy with radiotherapy for bone lesions (n=29); and those who underwent systemic therapy without radiotherapy for bone lesions (n=15). The radiographical efficacy of systemic therapy and the time to progression of bone metastases were compared between groups. The overall response rate of systemic therapy with radiotherapy was 44%, and in total, 13 patients demonstrated a partial response. Only one patient (6%) had a partial response among those who were treated via systemic therapy without radiotherapy. The time to progression of bone metastasis was 9.5 and 2.1 months in patients treated with and without radiotherapy, respectively (P<0.0001). Collectively, the present results suggested that targeted therapy or immune checkpoint inhibitors without radiotherapy had only a slight effect on bone metastasis control.
Identifiants
pubmed: 32989401
doi: 10.3892/ol.2020.12130
pii: OL-0-0-12130
pmc: PMC7517538
doi:
Types de publication
Journal Article
Langues
eng
Pagination
267Informations de copyright
Copyright: © Negishi et al.
Références
Eur J Cancer. 2019 Jan;107:79-85
pubmed: 30551078
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2012 Apr;23(4):973-80
pubmed: 21890909
Phys Med Rehabil Clin N Am. 2017 Feb;28(1):101-114
pubmed: 27912991
Int J Oncol. 2001 Aug;19(2):379-82
pubmed: 11445855
J Clin Oncol. 2004 Jul 15;22(14):2942-53
pubmed: 15254062
PLoS One. 2013 Dec 30;8(12):e83026
pubmed: 24386138
Urol Oncol. 2016 Oct;34(10):433.e1-8
pubmed: 27321354
Cancer Treat Rev. 2008 May;34(3):193-205
pubmed: 18313224
J Natl Compr Canc Netw. 2015 Jun;13(6):801-9; quiz 809
pubmed: 26085394
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Eur Urol. 2011 Oct;60(4):615-21
pubmed: 21741761
Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S4-13
pubmed: 14600587
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Br J Cancer. 2013 Jun 25;108(12):2470-7
pubmed: 23695024
Ann Med Surg (Lond). 2018 Jan 31;27:9-16
pubmed: 29511536
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Eur J Oncol Nurs. 2007;11 Suppl 2:S28-31
pubmed: 17768092
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Anticancer Res. 2016 Oct;36(10):5531-5536
pubmed: 27798926
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
Anticancer Res. 2016 Jun;36(6):2631-7
pubmed: 27272771
Spine (Phila Pa 1976). 2005 Oct 1;30(19):2186-91
pubmed: 16205345
J Clin Oncol. 2014 Sep 10;32(26):2886-93
pubmed: 25113770
Lancet Oncol. 2015 Oct;16(13):e498-509
pubmed: 26433823
Clin Cancer Res. 2018 Sep 1;24(17):4081-4088
pubmed: 29848570
Ann Oncol. 2015 Jun;26(6):1048-1057
pubmed: 25471332